Myocardial infarction
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Cases: Twenty patients aged between 18 and 50 year, who present with an acute ST-elevation myocardial infarction eligible for primary percutaneous coronary intervention. ;Family members: Forty of their first degree healthy family members of the patients presenting with the acute myocardial infarction (two family members per patient).;Controls: 20 healthy controls aged 18 years or above. Controls will be matched with the cases for age, gender and cardiovascular risk factors.
Exclusion criteria
Exclusion criteria: Cases: - If the index patient (suffering from the acute myocardial infarction) has one or more of the following factors present: o Age below 18 years o Diagnosis of vascular disease (e.g. previous myocardial infarction, CVA, etc) o Use of statins, anti-inflammatory agents or thrombocyte aggregation inhibitors (these drugs modulate epigenetic changes in in vitro studies) o Auto-immune diseases (e.g. rheumatoid arthritis) o Coagulation disorder o No living first degree family members aged 18 years or above o Presence of two or more of the following risk factors: § Hypertension § Hypercholesterolemia § Diabetes mellitus § Active smoking or an active smoking history within the last 10 years;Family members: - If the first degree relative (i.e. the participant) has one or more of the following factors present: o Age below 18 years o History of vascular disease (e.g. previous myocardial infarction, CVA, etc) o Use of statins, anti-inflammatory agents or thrombocyte aggregation inhibitors (these drugs modulate epigenetic changes in in vitro studies) o Signs or symptoms of a current infection (fever, chills) o Auto-immune diseases (e.g. rheumatoid arthritis) o Coagulation disorder Controls: - If the control has one or more of the following factors present: o Age below 18 years o History of vascular disease (e.g. previous myocardial infarction, CVA, etc) o A first degree family member with vascular disease (e.g. previous myocardial infarction, CVA, etc) o Family relationship with the cases o Use of statins, anti-inflammatory agents or thrombocyte aggregation inhibitors (these drugs modulate epigenetic changes in in vitro studies) o Signs or symptoms of a current infection (fever, chills) o Auto-immune diseases (e.g. rheumatoid arthritis) o Coagulation disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is H3K4 trimethylation in the promoter region of inflammatory cytokines and the genetic search for the exonic variant, which can be correlated to the exaggerated pro-inflammatory response. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the cytokine release by monocytes in response to stimulation with Toll-like Receptor(TLR)-agonists and the transformation of monocytes in foam cells. Also the specific blood platelet function in these patients will be examined. | — |
Countries
Netherlands
Outcome results
None listed